Cancer · 1995 · 70 citations · 26 references
MedicineOncologyPharmacologyChemotherapyDrug DeliveryRadionuclide TherapyChemotherapy Drug AdministrationHepatocellular Carcinoma PharmacotherapyLiver CancerPharmacokinetics Of Anticancer DrugsRadiation TherapyHepatic Arterial Infusion ChemotherapyHepatic Artery InterventionHepatobiliary Cancer RadiotherapyHepatocellular Carcinoma RadiotherapyHepatocellular Carcinoma TreatmentLiver Tumor TherapyMolecularly Targeted AgentsTransfemoral Access
BACKGROUND: Arterially administered iodized oil (Lipiodol) is selectively retained by hepatocellular carcinomas (HCCs), and has been used as a vehicle for delivery of therapeutic agents to these tumors. This study compared the efficacy of Lipiodol-targeted epirubicin chemotherapy with Lipiodol-131I radiotherapy. METHODS: Ninety-five patients with unresectable HCC confined to the liver were administered either Lipiodol-epirubicin emulsion (n = 69; 61 cirrhotics; Okuda tumor Stage I, 14; II, 37; III, 18; epirubicin dose, 75 mg/m2) or Lipiodol-131I (131I) (n = 26; 18 cirrhotics; Okuda tumor Stage I, 6; II, 19; III, 1; dose 750-1050 MBq). The last 28 patients (17 epirubicin, 11 131I) were treated within a prospective randomized trial. Bolus drug or isotope was injected into the hepatic artery by transfemoral cannulation. Lipiodol and 131I uptake were gauged by 10th day computed tomography and 48-hour scintiscan. Treatments were repeated two-monthly when indicated. RESULTS: Tumor size at 2 months remained static or diminished partially in 21 of 38 epirubicin recipients (55%) and 15/22 131I recipients (68%). Actuarial survival at 6, 12, and 24 months was 40%, 25%, and 6% with epirubicin, and 58%, 25%, and 0% with 131I; 30-day mortality was 11% and 15%, respectively. Comparison with historic controls indicated survival benefit in Stages I and II. Similar findings were recorded in the 28 patients in the randomized trial. CONCLUSIONS: Patients with unresectable HCC receiving Lipiodol-epirubicin or Lipiodol-131I show good tumor localization, acceptable toxicity, and comparable survival benefit at 6 and 12 months with either modality.
26
Transection of the oesophagus for bleeding oesophageal varices
R. N. H. Pugh, I M Murray-Lyon, J L Dawson et al. · British journal of surgery · 1973 · 8K citations
Kunio Okuda, Toshio Ohtsuki, Hiroshi Obata et al. · Cancer · 1985 · 1.9K citations · Full text
A 5-Year Study of Cryosurgery in the Treatment of Liver Tumors
T.S. Ravikumar · Archives of Surgery · 1991 · 264 citations